Drug Trial Radar · NCT03098030
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Dec 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
483
Actual
Start
Jun 1, 2017
Primary completion
Jan 27, 2020
Study completion Mar 26, 2020
Sponsor
- Lead sponsor
- United TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 31, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part, multicenter, open-label, randomized study of dinutuximab and irinotecan versus irinotecan alone in subjects with relapsed or refractory small cell lung cancer (SCLC). Part 1 of the study involves intrasubject dose escalation to evaluate the safety and tolerability of dinutuximab in combination with irinotecan. Part 2 of the study is designed to determine whether dinutuximab plus irinotecan prolongs overall survival (OS) compared with irinotecan alone. Subjects in Part 2 will be randomized in a 2:2:1 fashion to 1 of 3 treatment groups: (A) irinotecan; (B) dinutuximab plus irinotecan; or (C) topotecan. Randomization will be stratified by duration of response to prior platinum therapy (relapse-free period \<3 months or ≥3 months).
Conditions
- Small Cell Lung Cancer
Interventions
DinutuximabBiological
Dinutuximab injection, for intravenous (IV) use
IrinotecanDrug
Irinotecan injection, IV infusion
TopotecanDrug
Topotecan for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 2.5 years
Locations
226 sites in 23 countries. Site status is shown where the registry gives one.
Alaska Clinical Research Center
Anchorage, Alaska
Cancer Treatment Centers of America - Western Regional Medical Center
Goodyear, Arizona
Innovative Clinical Research Institute
Tucson, Arizona
Genesis Cancer Center
Hot Springs, Arkansas
USC Norris Comprehensive Cancer Center
Los Angeles, California
VA Palo Alto Health Care System
Palo Alto, California
Olive View - UCLA
Sylmar, California
Innovative Clinical Research Institute
Whittier, California
Hartford Hospital
Hartford, Connecticut
Eastern Connecticut Hematology and Oncology Assoc
Norwich, Connecticut
Alpha Oncology Research LLC
DeBary, Florida
21st Century Oncology
Jacksonville, Florida
Comprehensive Hematology Oncology
St. Petersburg, Florida
Winship Cancer Institute, Emory University
Atlanta, Georgia
Northwest Georgia Oncology Centers, P.C.
Marietta, Georgia
Baptist Health Floyd Cancer Center
New Albany, Indiana
Physicians' Clinic of Iowa Hematology and Oncology
Cedar Rapids, Iowa
Kentucky Cancer Clinic
Hazard, Kentucky
University of Kentucky
Lexington, Kentucky
21st Century Oncology
Louisville, Kentucky
Cox Health Medical
Springfield, Missouri
Billings Clinic Cancer Center
Billings, Montana
St. Vincent Frontier Cancer Center
Billings, Montana
The University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico
UH Cleveland Medical Center
Cleveland, Ohio
Cancer Treatment Centers of America at Southwestern RMC
Tulsa, Oklahoma
Kaiser Permanente Northwest Center for Health Research CRSS
Portland, Oregon
Fox Chase Cancer Center Office of Clinical Research
Philadelphia, Pennsylvania
Cancer Treatment Centers of America at Eastern Regional Medical Center
Philadelphia, Pennsylvania
Charleston Oncology
Charleston, South Carolina
Spartanburg Medical Center/Gibbs Cancer Center and Research Institute
Spartanburg, South Carolina
Prairie Lakes Health Care
Watertown, South Dakota
Center for Biomedical Research
Knoxville, Tennessee
Texas Health Physicians Group
Arlington, Texas
Plano Cancer Institute
Plano, Texas
The University of Texas Health Science Center at Tyler, Office of Clinical Studies
Tyler, Texas
Vista Oncology (Shelton office)
Shelton, Washington
United Hospital Center
Bridgeport, West Virginia
Camden Clark Medical Center / Regional Cancer Center
Parkersburg, West Virginia
University of Wisoncsin - Carbone Cancer Ctr
Madison, Wisconsin
Showing 40 of 226 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.